IL143759A0 - STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS - Google Patents
STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORSInfo
- Publication number
- IL143759A0 IL143759A0 IL14375999A IL14375999A IL143759A0 IL 143759 A0 IL143759 A0 IL 143759A0 IL 14375999 A IL14375999 A IL 14375999A IL 14375999 A IL14375999 A IL 14375999A IL 143759 A0 IL143759 A0 IL 143759A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical formulation
- hmg
- coa reductase
- reductase inhibitors
- pravastatin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title abstract 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 2
- 229960005370 atorvastatin Drugs 0.000 abstract 2
- 238000000855 fermentation Methods 0.000 abstract 2
- 230000004151 fermentation Effects 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960002965 pravastatin Drugs 0.000 abstract 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 241000894007 species Species 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 abstract 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 abstract 1
- 241000187643 Amycolatopsis Species 0.000 abstract 1
- 241000228212 Aspergillus Species 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 1
- 241000235395 Mucor Species 0.000 abstract 1
- 241000187654 Nocardia Species 0.000 abstract 1
- 241000228143 Penicillium Species 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI9800309A SI20109A (sl) | 1998-12-16 | 1998-12-16 | Stabilna farmacevtska formulacija |
| PCT/IB1999/001749 WO2000035425A1 (en) | 1998-12-16 | 1999-10-29 | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143759A0 true IL143759A0 (en) | 2002-04-21 |
Family
ID=20432372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14375999A IL143759A0 (en) | 1998-12-16 | 1999-10-29 | STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS |
| IL143759A IL143759A (en) | 1998-12-16 | 2001-06-14 | Stable pharmaceutical formulation containing HMG COA REDUCTASE inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL143759A IL143759A (en) | 1998-12-16 | 2001-06-14 | Stable pharmaceutical formulation containing HMG COA REDUCTASE inhibitor |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6680341B1 (cs) |
| EP (2) | EP1911445A3 (cs) |
| JP (1) | JP2002532409A (cs) |
| KR (1) | KR100638307B1 (cs) |
| CN (1) | CN1198597C (cs) |
| AT (1) | ATE380020T1 (cs) |
| AU (1) | AU775946B2 (cs) |
| BG (1) | BG105559A (cs) |
| CA (1) | CA2348988C (cs) |
| CZ (1) | CZ302562B6 (cs) |
| DE (1) | DE69937691T2 (cs) |
| ES (1) | ES2299265T3 (cs) |
| HR (1) | HRP20010325A2 (cs) |
| HU (1) | HUP0104258A3 (cs) |
| IL (2) | IL143759A0 (cs) |
| IS (1) | IS5939A (cs) |
| NZ (1) | NZ511260A (cs) |
| PL (1) | PL347686A1 (cs) |
| RU (1) | RU2227019C2 (cs) |
| SI (2) | SI20109A (cs) |
| SK (1) | SK8092001A3 (cs) |
| TR (1) | TR200101235T2 (cs) |
| WO (1) | WO2000035425A1 (cs) |
| YU (1) | YU35501A (cs) |
| ZA (1) | ZA200103802B (cs) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| PT1274401E (pt) | 2000-04-10 | 2011-12-02 | Teva Pharma | Composições farmacêuticas estáveis contendo ácidos 7-substituídos-3,5-di-hidroxi-heptanóicos ou ácidos 7-substituídos-3,5-di-hidroxi-heptenóicos |
| US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| SI1292293T1 (en) | 2000-06-09 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| DE60041281D1 (de) † | 2000-06-09 | 2009-02-12 | Lek Pharmaceuticals | Stabilisiertes arzneimittel und arzneizubereitung |
| US20050215636A1 (en) * | 2000-10-05 | 2005-09-29 | Vilmos Keri | Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| JP2004527518A (ja) * | 2001-03-27 | 2004-09-09 | ランバクシー ラボラトリーズ リミテッド | プラバスタチンの安定薬剤組成物 |
| GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| CA2450001A1 (en) * | 2001-06-21 | 2003-01-03 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions containing pravastatin |
| JP2003055217A (ja) * | 2001-08-10 | 2003-02-26 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
| EP1905431A1 (en) * | 2002-01-11 | 2008-04-02 | Circ Pharma Research and Development Limited | Pravastatin pharmaceutical formulations and methods of their use |
| US6967218B2 (en) | 2002-01-11 | 2005-11-22 | Biovail Laboratories, Inc. | Pravastatin pharmaceutical formulations and methods of their use |
| US20030175338A1 (en) * | 2002-02-14 | 2003-09-18 | Singh Romi Barat | Formulations of atorvastatin stabilized with alkali metal additions |
| CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| SE0202365D0 (sv) * | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
| CA2497896A1 (en) * | 2002-09-03 | 2004-03-18 | Biovail Laboratories Inc. | Pravastatin pharmaceutical formulations and methods of their use |
| BR0317593A (pt) | 2002-12-20 | 2005-11-22 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
| EP1737449A1 (en) * | 2004-03-01 | 2007-01-03 | LEK Pharmaceuticals D.D. | Pharmaceutical composition |
| KR100598326B1 (ko) | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
| WO2006008757A2 (en) * | 2004-05-05 | 2006-01-26 | Cadila Healthcare Limited | Stabilized pharmaceutical compositions of pravastatin |
| KR20070052760A (ko) * | 2004-08-06 | 2007-05-22 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 페노피브레이트 제제 및 관련된 치료방법 |
| BRPI0514189A (pt) * | 2004-08-06 | 2008-06-03 | Transform Pharmaceuticals Inc | composições farmacêuticas de estatina e métodos de tratamento relacionados |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| CA2588216A1 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| CA2615941A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| US20090247603A1 (en) | 2005-12-23 | 2009-10-01 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| WO2008062476A2 (en) * | 2006-10-31 | 2008-05-29 | Glenmark Pharmaceutical Limited | Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof |
| BG934U1 (bg) * | 2006-12-14 | 2007-11-30 | "Софарма" Ад | Състав за твърда лекарствена форма, съдържащ правастатин |
| US20100196469A1 (en) * | 2007-06-25 | 2010-08-05 | Pharmathen S.A. | Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof |
| GB0713707D0 (en) * | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| DE102007052071A1 (de) | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
| JPWO2011049122A1 (ja) * | 2009-10-21 | 2013-03-14 | 第一三共株式会社 | プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法 |
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
| EP2664328B2 (en) | 2010-06-30 | 2022-04-27 | Mochida Pharmaceutical Co., Ltd. | Omega3 fatty acid compound preparation |
| TR201005326A2 (tr) | 2010-06-30 | 2012-01-23 | B�Lg�� Mahmut | Çoklu dozaj formları. |
| US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
| US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
| US9399064B2 (en) | 2011-04-12 | 2016-07-26 | Sawai Pharmaceutical Co., Ltd. | Pitavastatin-containing preparation and method for producing same |
| WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| US9308190B2 (en) | 2011-06-06 | 2016-04-12 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
| IN2014CN04119A (cs) | 2011-11-15 | 2015-07-10 | Reddys Lab Ltd Dr | |
| KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
| EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US579837A (en) * | 1897-03-30 | Saw-sharpening machine | ||
| MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| SG45369A1 (en) * | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| IL118778A (en) * | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
| EP0814782B1 (en) * | 1995-12-22 | 2002-11-27 | Kowa Company Ltd. | Pharmaceutical composition stabilized with a basic agent |
| FR2751316B1 (fr) * | 1996-07-19 | 1998-08-28 | Granger Maurice | Appareil distributeur de bandes de papier ouate pour essuie-mains, papier toilette et similaire |
| FR2751540B1 (fr) * | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| SI1292293T1 (en) * | 2000-06-09 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| SI21302A (sl) * | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| TW589178B (en) * | 2003-02-21 | 2004-06-01 | China Chemical & Pharmaceutica | A novel industrial process to obtain pravastatin sodium of high purity |
-
1998
- 1998-12-16 SI SI9800309A patent/SI20109A/sl not_active IP Right Cessation
-
1999
- 1999-10-29 HR HR20010325A patent/HRP20010325A2/hr not_active Application Discontinuation
- 1999-10-29 NZ NZ511260A patent/NZ511260A/xx unknown
- 1999-10-29 SI SI9931000T patent/SI1148872T1/sl unknown
- 1999-10-29 RU RU2001115716/15A patent/RU2227019C2/ru not_active IP Right Cessation
- 1999-10-29 YU YU35501A patent/YU35501A/sh unknown
- 1999-10-29 EP EP07122298A patent/EP1911445A3/en not_active Withdrawn
- 1999-10-29 IL IL14375999A patent/IL143759A0/xx unknown
- 1999-10-29 SK SK809-2001A patent/SK8092001A3/sk unknown
- 1999-10-29 JP JP2000587746A patent/JP2002532409A/ja active Pending
- 1999-10-29 CZ CZ20011727A patent/CZ302562B6/cs not_active IP Right Cessation
- 1999-10-29 HU HU0104258A patent/HUP0104258A3/hu unknown
- 1999-10-29 EP EP99951034A patent/EP1148872B1/en not_active Expired - Lifetime
- 1999-10-29 ES ES99951034T patent/ES2299265T3/es not_active Expired - Lifetime
- 1999-10-29 AT AT99951034T patent/ATE380020T1/de active
- 1999-10-29 WO PCT/IB1999/001749 patent/WO2000035425A1/en active IP Right Grant
- 1999-10-29 TR TR2001/01235T patent/TR200101235T2/xx unknown
- 1999-10-29 KR KR1020017006808A patent/KR100638307B1/ko not_active Expired - Fee Related
- 1999-10-29 CA CA002348988A patent/CA2348988C/en not_active Expired - Fee Related
- 1999-10-29 DE DE69937691T patent/DE69937691T2/de not_active Expired - Lifetime
- 1999-10-29 US US09/600,436 patent/US6680341B1/en not_active Expired - Fee Related
- 1999-10-29 CN CNB998144037A patent/CN1198597C/zh not_active Expired - Fee Related
- 1999-10-29 PL PL99347686A patent/PL347686A1/xx unknown
- 1999-10-29 AU AU63608/99A patent/AU775946B2/en not_active Ceased
-
2001
- 2001-05-10 ZA ZA200103802A patent/ZA200103802B/en unknown
- 2001-05-15 IS IS5939A patent/IS5939A/is unknown
- 2001-06-04 BG BG105559A patent/BG105559A/xx unknown
- 2001-06-14 IL IL143759A patent/IL143759A/en not_active IP Right Cessation
-
2003
- 2003-09-04 US US10/655,263 patent/US20040072894A1/en not_active Abandoned
-
2008
- 2008-07-11 US US12/172,143 patent/US20090264497A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143759A0 (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS | |
| PL362764A1 (en) | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same | |
| IL187261A0 (en) | Crystals of the sodium salt of pravastatin | |
| IL142055A0 (en) | New salts of hmg-coa reductase inhibitors | |
| YU81800A (sh) | POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE | |
| WO2000048626A3 (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease | |
| AU1510800A (en) | Process for the preparation of simvastatin and analogs thereof | |
| AU2000250960A1 (en) | Stable pharmaceutical product and formulation | |
| US7230120B2 (en) | Amorphous HMG-CoA reductase inhibitors of desired particle size | |
| YU88602A (sh) | Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže |